Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV

Recruiting in Palo Alto (17 mi)

+32 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group

No Placebo Group

Trial Summary

What is the purpose of this trial?

IMPAACT 2028 is an observational prospective study to characterize a cohort of early treated children who may participate in future research related to HIV remission or cure. Up to approximately 250 participants will be in the study for approximately seven years. No intervention is provided in the study.

Research Team

Shaun Barnabas, MD, PhD

Principal Investigator

University of Stellenbosch

Samantha Fry, MD, MMed

Principal Investigator

University of Stellenbosch

Julia Rosebush, DO, FAAP

Principal Investigator

University of Chicago

Eligibility Criteria

Inclusion Criteria

Participated in one of the parent studies

Confirmed HIV-1 infection based on documented nucleic acid testing of two blood samples collected at different time points

Received early treatment for HIV-1 infection, defined as treatment with at least three ARV agents from at least two classes of ART, initiated within 12 weeks of birth

See 2 more

Treatment Details

Interventions

NA (NA)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Cohort 1Experimental Treatment1 Intervention

Children living with perinatally-acquired HIV who received early treatment in IMPAACT network studies or other research studies sponsored by the United States National Institutes of Health.